Investigations before OLT, Immunosuppression and rejection, Follow up after OLT.

Similar documents
Approach to the Patient with Liver Disease

Learning Objectives. After attending this presentation, participants will be able to:

A Review of Liver Function Tests. James Gray Gastroenterology Vancouver

Steps in Assessing Fibrosis 4/30/2015. Overview of Liver Disease Associated With HCV

Long term liver transplant management

Cirrhosis and Portal Hypertension Gastroenterology Teaching Project American Gastroenterological Association

Hepatocytes produce. Proteins Clotting factors Hormones. Bile Flow

Transplant Hepatology

Are we adequately screening at-risk patients for hepatocellular carcinoma in the outpatient setting?

Supplemental Tables. Parasitic Schistosomiasis increase < 1. Genetic Hemochromatosis increase < 1. autoimmune Autoimmune hepatitis (AIH) increase < 1

Approach to Abnormal Liver Tests

The Yellow Patient. Dr Chiradeep Raychaudhuri, Consultant Hepatologist, Hull University Teaching Hospitals NHS Trust

CIRROSI E IPERTENSIONE PORTALE NELLA DONNA

Hepatocellular Carcinoma (HCC)

EVALUATION OF ABNORMAL LIVER TESTS

Liver Transplant: What s Different? Brian Lin, MD, FACEP Emergency Medicine, Kaiser Permanente, San Francisco UCSF Clinical Assistant Professor

End Stage Liver Disease & Disease Specific Indications for Liver Transplant. Susan Kang, RN, MSN, ANP-BC

End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC

Supplementary Digital Content

How to improve long term outcome after liver transplantation?

But. therefore, I: Liver Transplantation a non transplant centre perspective HOW AM I QUALIFIED TO DO THIS?

European. Young Hepatologists Workshop. Organized by : Quantification of fibrosis and cirrhosis outcomes

Hepatocellular Carcinoma: Diagnosis and Management

Liver failure &portal hypertension

Viral hepatitis. Supervised by: Dr.Gaith. presented by: Shaima a & Anas & Ala a

Overall Goals and Objectives for Transplant Hepatology EPAs:

Initial Evaluation for HCV Therapy. Hope McGratty PA-C, MPH

Acute Liver Failure. Neil Shah, MD UNC School of Medicine High-Impact Hepatology Saturday, Dec 8 th, 2018

What Is Cirrhosis? CIRRHOSIS. Cirrhosis occurs when the liver is. by chronic conditions and diseases. permanently scarred or injured

Hepatology For The Nonhepatologist

Liver Transplantation Evaluation: Objectives

ABNORMAL LIVER FUNCTION TESTS. Dr Uthayanan Chelvaratnam Hepatology Consultant North Bristol NHS Trust

Workup of a Solid Liver Lesion

Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary)

Hepatitis. Dr. Mohamed. A. Mahdi 5/2/2019. Mob:

Contraindications. Indications. Complications. Currently TIPS is considered second or third line therapy for:

Liver Transplantation

British Liver Transplant Group Pathology meeting September Leeds cases

Acute Hepatitis: An Approach to Infectious and Other Causes. Mary Anne Cooper MSc, MD, MEd, FRCPC

Overview of PSC Jayant A. Talwalkar, MD, MPH Associate Professor of Medicine Mayo Clinic Rochester, MN

Treatment of recurent hepatitis infection after liver transplantation

The Liver for the Nonhepatologist

World Health Organization. Western Pacific Region

Western Health Specialist Clinics Access & Referral Guidelines

Patterns of abnormal LFTs and their differential diagnosis

Management of autoimmune hepatitis. Pierre-Emmanuel RAUTOU Inserm U970, Paris Service d hépatologie, Hôpital Beaujon, Clichy, France

DISEASE LEVEL MEDICAL EVIDENCE PROTOCOL

Life After SVR for Cirrhotic HCV

Etiology of liver cirrhosis

Liver Cancer: Diagnosis and Treatment Options

Evaluating HIV Patient for Liver Transplantation. Marion G. Peters, MD Professor of Medicine University of California San Francisco USA

Management of Cirrhosis Related Complications

Surveillance for HCC Who, how Diagnosis of HCC Surveillance for HCC in Practice

Module 1 Introduction of hepatitis

Chronic Hepatitis B Infection

Screening for Portal Hypertension in Cirrhosis

Nordic Liver Transplant Registry

Management of HepatoCellular Carcinoma

Liver Transplantation By: Kay R. Brown, CLCP

B C Outlines. Child-Pugh scores

The Liver for the Nonhepatologist

Diagnostic Procedures. Measurement of Hepatic venous pressure in management of cirrhosis. Clinician s opinion

HEPATOCELLULAR CARCINOMA: SCREENING, DIAGNOSIS, AND TREATMENT

Hepatology for the Nonhepatologist

Chronic liver allograft dysfunction. An unsolved problem

Jong Young Choi, M.D.

Clinical Trials & Endpoints in NASH Cirrhosis

Viral Hepatitis And Liver Transplantation

Causes of Liver Disease in US

End-Stage Liver Disease (ESLD): A Guide for HIV Physicians

PROGRAMME AT A GLANCE

I have no disclosures relevant to this presentation LIVER TESTS: WHAT IS INCLUDED? LIVER TESTS: HOW TO UTILIZE THEM OBJECTIVES

The Chronic Liver Disease Foundation (CLDF) and the International Coalition of Hepatology Education Providers (IC-HEP) present:

Patterns of abnormal LFTs and their differential diagnosis

Novel Therapies in Autoimmune Hepatitis

Emricasan (IDN-6556) administered orally for 28 days lowers portal pressure in patients with compensated cirrhosis and severe portal hypertension

The future of liver transplantation for viral hepatitis

Laboratory Tests and Diagnostic Procedures in Liver Disease: Adventures in Liverland

The Sheila Sherlock Royal Free Hepatology Postgraduate Course Date: 15 th 17 th May 2019 Location: Royal Free Hospital, London, United Kingdom

Chronic liver failure Assessment for liver transplantation

Definition: fibrosis and nodular regeneration resulting from hepatocellular injury

EVALUATION & LISTING. Your Child s Liver Transplant Evaluation. What is the Liver?

ESLD a Guide for HIV Physicians. Marion Peters University of California San Francisco June 2015

DIFFERENTIAL BENEFITS OF DAAs IN DIFFERENT PATIENT POPULATIONS. IN PATIENTS ON A WAITING LIST FOR TRANSPLANTATION. THE CLINIC.

Cirrhosis is different from Fibrosis

Hepatitis and pregnancy

Trapianto di fegato e organi solidi. Pierluigi Toniutto Sezione di Epatologia e Trapianto Epatico Università di Udine

WEEK. MPharm Programme. Liver Biochemistry. Slide 1 of 49 MPHM14 Liver Biochemistry

Hepatitis C Update on New Treatments

Gastroenterology. Certification Examination Blueprint. Purpose of the exam

Prognosis of untreated Primary Sclerosing Cholangitis (PSC) Erik Christensen Copenhagen, Denmark

ASSESSMENT AND MANAGEMENT OF POTENTIAL LIVER TRANSPLANT CANDIDATES

Noncalculous Biliary Disease Dean Abramson, M.D. Gastroenterologists, P.C. Cedar Rapids. Cholestasis

Hepatitis Alert: Management of Patients With HCV Who Have Achieved SVR

Hepatitis C: New Antivirals in the Liver Transplant Setting. Maria Carlota Londoño Liver Unit Hospital Clínic Barcelona

LIVER CIRRHOSIS. The liver extracts nutrients from the blood and processes them for later use.

Hepatitis C: How sick can we treat? Robert S. Brown, Jr., MD, MPH Vice Chair, Transitions of Care Interim Chief, Division of

Gastrointestinal System: Accessory Organ Disorders

PITFALLS IN THE DIAGNOSIS OF MEDICAL LIVER DISEASE WITH TWO CONCURRENT ETIOLOGIES I HAVE NOTHING TO DISCLOSE CURRENT ISSUES IN ANATOMIC PATHOLOGY 2017

Transcription:

Investigations before OLT, Immunosuppression and rejection, Follow up after OLT andrea.degottardi@insel.ch

When is liver transplantation indicated?

When is liver transplantation indicated? Frequent: CIRRHOSIS a) Viral Hepatitis HCV HBV HDV b) ALD c) NASH HCC Rare a) Autoimmune PBC AIH PSC b) Cryptogenic c) Metabolic diseases Hemochromatosis Alpha-1-AT deficiency Wilsons disease e) others Budd-Chiari Policystic liver disease Amyloidosis

When is liver transplantation indicated? Histology F1-F3 F4 (cirrhosis) Clinical Non cirrhotic Stable Stable Decompensated Symptoms None None Jaundice/Varices Complications Gradient < 6 mmhg 6-10 mmhg 10-12 mmhg > 12 mmhg Biology Fibrogenesis/A ngiogenesis Scar Scar/ Microthrombosis Carcinogenesis Elastography 8-14 KPa 14-75 KPa modif. after Garcia-Tsao, Hepatology, 2010

decompensated compensated When is liver transplantation indicated? NO VARICES NO ASCITES VARICES NO ASCITES 7% 7% 1% 3-5% median survival 12 years 1-year mortality ASCITES +/- VARICES VARICEAL BLEEDING+/- ASCITES 8% 15-20% 40-60% median survival 2-3 years El Serag, Am J Gastro, 2000. D Amico, Gastroenterology, 2001. Stokkeland, Hepatology, 2006

When is liver transplantation indicated? Hernandez-Gea, Am J Gastro, 2012

MELD Score Model for End-Stage Liver Disease 6-40 9.57xlog creatinine + 3.78xlog bilirubin + 11.12xlog INR + 6.4

3-Month survival MELD R Wiesner et al, Gastroenterology 2003;124:91-96

How to select the right time point for OLT listing

How to select the right time point for OLT listing

How to select the right time point for OLT listing

How to select the right time point for OLT listing The exception with HCC

Question

Acute liver failure 1) Drug or alimentary toxicity (mushrooms) 2) Viral hepatitis: HBV, Herpes, HEV 3) Budd-Chiari syndrome Clichy criteria: presence of hepatic encephalopathy + factor V level <20% (age < 30) or <30 %

Acute liver failure Clichy criteria: presence of hepatic encephalopathy + factor V level <20% (age < 30) or <30 % King s College criteria: - paracetamol induced or other - art. ph < 7.30 - INR > 3.5 - Creatinine > 300 um - Bili > 300 um - Age < 10 or > 40 years - Jaundice to HE time > 7 days

Essential investigations before OLT Laboratory: Liver and kidney function Serologies (CMV!) Blood group Radiology: Anatomy of the liver, vessels, HCC Staging (CT, MRI) Interdisciplinary evaluation: - ID - anesthesia - psychiatry Endoscopy: Upper and lower GI Heart and lungs: stress-ecg LUFU

IMMUNOSUPPRESSION Commonly used drugs Follow up visits 2-4 W 2/W 1-2 Mo 1/W after 3 Mo every 4-6 W

Wirkungsmechanismen

IMMUNOSUPPRESSION Main side effects PRED CYS TAC MMF mtor

Early Follow up after OLT Early complications 1. Primary non function 2. Thrombosis or stenosis of the hepatic art. 3. Portal vein thrombosis 4. Biliary leakage or anastomosis stricture

Early Follow up after OLT Early complications

Long term follow up: complications 1. Rejection 2. Infections 3. HCC relapse 4. arterial hypertension 5. Osteoporosis 6. Kidney dysfunction/insufficiency 7. (skin-) Tumors Liver Transplantation; Martin ed.; in Clinics in Liver Disease; 11, 2, 2007 Medical Care of the Liver Transplant Patient; Kilemberg & Clavien eds; Blackwell Science, 1997

Rejection Acute rejection 1. 4-14 days after OLT 2. no specific symptoms 3. Lab: cholestasis 4. biopsy needed for diagnosis 5. treatment with steroids Chronic rejection 1. first 6 months after OLT 2. obstruction of small arteries and ductopenia 3. jaundice 4. biopsy needed for diagnosis 5. treatment with steroids and increased IS

Infections 1. Frequent in the first 12 months 2. Bacterial infections 3. Viral infections CMV HZV HSV 4. fungi Candida Albicans Aspergillus Fumigatus Criptococcus Neoformans 5. Protozoa Pneumocistis Carinii

Bacterial infections 1. Most frequent during the first 8 weeks after OLT 2. Clinical manifestations Abdominal (Peritonitis, Cholangitis, Abscess) Pneumonia Wound infections Becteremia of unknown origin 3. Bacteria intestinal Enterokokken Escherichia Coli other S. Aureus Klebsiella Pneumoniae Pneumokokken Legionellen Nocardia

CMV 1. 23-85% 2. 50% asymptomatic 3. Viral origin Transplanted organ Blood transfusions Reactivation 4. Symptoms cold pneumonia GI (nausea, vomiting, diarrhea) Hepatitis 5. Diagnosis: PCR, liver biopsy, coloscopy with biopsies

HBV 1. <10% with HBIg + Lamivudin 2. Hepatect or Zutectra HCV 1. 100% 2. Treatment lergely possible with new antivirals, for example Sofosbuvir/Ledipasvir

HCC-relapse (<10%) 1. Switch IS to mtor inhibitors 2. Surgical resection 3. TAE 4. RFA 5. Radiation therapy 6. Sorafenib

Arterial hypertension 1. Prevalence >70% 2. Etiology: IS, in particular Prednisone, Ciclosporine or Tacrolimus 3. Therapy: ACE inhibitor Hyper-K with IS Leucopenia mit MMF Calcium antagonists (Amlodipine)

Diabetes and overweight 1. Very frequent! 2. Therapy like in the non transplanted population, based on adequate diet and physical activity Lipid metabolism 1. Increaed cholesterol with mtor inhibitors 2. Treatment using Statins (Pravastatin, Atorvastatin)

Kidney insufficiency 1. Frequent! Up to 20 % after 5 years 2. Aetiology: Ciclosporine (CSA) Tacrolimus (FK) Scarring of the parenchyma Microthromboses Tubular atrophy 3. Treatment Immunosuppression low dose (Plasmalevels) Switch to mtor inhibitors

Kidney insufficiency

Neoplasia 1. Affects long-term mortality 2. incidence: 2-26% 3. Maily skin tumors (Basalioma, Melanoma) and Lymphomas (PTLD) 4. Risk factors: age smoke alcohol High immunosuppression EBV (de novo/reactivation) 5. Screening is important! - Dermatology

Question

Question

Family planning Contraception: Oral contraceptive pill has no CI. If older than 35 consider other possibilities. Avoid smoking. Pregnancy. Possible one year after OLT. Monitoring is important because of premature birth